Corresponding Author: Karina W. Davidson, PhD, MASc, Feinstein Institutes for Medical Research, 130 E 59th St, Ste 14C, New York, NY 10032 (chair@uspstf.net).
Accepted for Publication: October 26, 2021.
The US Preventive Services Task Force (USPSTF) members: Karina W. Davidson, PhD, MASc; Michael J. Barry, MD; Carol M. Mangione, MD, MSPH; Michael Cabana, MD, MA, MPH; Aaron B. Caughey, MD, PhD; Esa M. Davis, MD, MPH; Katrina E. Donahue, MD, MPH; Chyke A. Doubeni, MD, MPH; Martha Kubik, PhD, RN; Li Li, MD, PhD, MPH; Gbenga Ogedegbe, MD, MPH; Lori Pbert, PhD; Michael Silverstein, MD, MPH; James Stevermer, MD, MSPH; Chien-Wen Tseng, MD, MPH, MSEE; John B. Wong, MD.
Affiliations of The US Preventive Services Task Force (USPSTF) members: Feinstein Institutes for Medical Research at Northwell Health, Manhasset, New York (Davidson); Harvard Medical School, Boston, Massachusetts (Barry); University of California, Los Angeles (Mangione); Albert Einstein College of Medicine, New York, New York (Cabana); Oregon Health & Science University, Portland (Caughey); University of Pittsburgh, Pittsburgh, Pennsylvania (Davis); University of North Carolina at Chapel Hill (Donahue); Mayo Clinic, Rochester, Minnesota (Doubeni); George Mason University, Fairfax, Virginia (Kubik); University of Virginia, Charlottesville (Li); New York University, New York, New York (Ogedegbe); University of Massachusetts Medical School, Worcester (Pbert); Boston University, Boston, Massachusetts (Silverstein); University of Missouri, Columbia (Stevermer); University of Hawaii, Honolulu (Tseng); Pacific Health Research and Education Institute, Honolulu, Hawaii (Tseng); Tufts University School of Medicine, Boston, Massachusetts (Wong).
Author Contributions: Dr Davidson had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The USPSTF members contributed equally to the recommendation statement.
Conflict of Interest Disclosures: Authors followed the policy regarding conflicts of interest described at https://www.uspreventiveservicestaskforce.org/Page/Name/conflict-of-interest-disclosures. All members of the USPSTF receive travel reimbursement and an honorarium for participating in USPSTF meetings.
Funding/Support: The USPSTF is an independent, voluntary body. The US Congress mandates that the Agency for Healthcare Research and Quality (AHRQ) support the operations of the USPSTF.
Role of the Funder/Sponsor: AHRQ staff assisted in the following: development and review of the research plan, commission of the systematic evidence review from an Evidence-based Practice Center, coordination of expert review and public comment of the draft evidence report and draft recommendation statement, and the writing and preparation of the final recommendation statement and its submission for publication. AHRQ staff had no role in the approval of the final recommendation statement or the decision to submit for publication.
Disclaimer: Recommendations made by the USPSTF are independent of the US government. They should not be construed as an official position of AHRQ or the US Department of Health and Human Services.
Additional Contributions: We thank Iris Mabry-Hernandez, MD, MPH, and Sheena Harris, MD, MPH (AHRQ), who contributed to the writing of the manuscript, and Lisa Nicolella, MA (AHRQ), who assisted with coordination and editing.
Additional Information: The US Preventive Services Task Force (USPSTF) makes recommendations about the effectiveness of specific preventive care services for patients without obvious related signs or symptoms. It bases its recommendations on the evidence of both the benefits and harms of the service and an assessment of the balance. The USPSTF does not consider the costs of providing a service in this assessment. The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decision-making to the specific patient or situation. Similarly, the USPSTF notes that policy and coverage decisions involve considerations in addition to the evidence of clinical benefits and harms. Published by JAMA®–Journal of the American Medical Association under arrangement with the Agency for Healthcare Research and Quality (AHRQ). ©2021 AMA and United States Government, as represented by the Secretary of the Department of Health and Human Services (HHS), by assignment from the members of the United States Preventive Services Task Force (USPSTF). All rights reserved.
1.Chou
R , Pappas
M , Dana
T , Selph
S , Hart
E , Schwarz
E . Screening and Prevention of Dental Caries in Children Younger Than Five Years of Age: A Systematic Review for the US Preventive Services Task Force. Evidence Synthesis No. 210. Agency for Healthcare Research and Quality; 2021. AHRQ publication 21-05279-EF-1.
4.Centers for Disease Control and Prevention. Oral Health Surveillance Report: Trends in Dental Caries and Sealants, Tooth Retention, and Edentulism, United States, 1999-2004 to 2011-2016. Centers for Disease Control and Prevention; 2019.
5.Dye
BA , Mitnik
GL , Iafolla
TJ , Vargas
CM . Trends in dental caries in children and adolescents according to poverty status in the United States from 1999 through 2004 and from 2011 through 2014.
J Am Dent Assoc. 2017;148(8):550-565. doi:
10.1016/j.adaj.2017.04.013PubMedGoogle ScholarCrossref 9.Dooley
D , Moultrie
NM , Heckman
B , Gansky
SA , Potter
MB , Walsh
MM . Oral health prevention and toddler well-child care: routine integration in a safety net system.
Pediatrics. 2016;137(1):e20143532. doi:
10.1542/peds.2014-3532PubMedGoogle Scholar 10.Institute of Medicine and National Research Council. Improving Access to Oral Health Care for Vulnerable and Underserved Populations. National Academies Press; 2011.
12.Garcia
RI , Gregorich
SE , Ramos-Gomez
F ,
et al. Absence of fluoride varnish-related adverse events in caries prevention trials in young children, United States.
Prev Chronic Dis. 2017;14:E17. doi:
10.5888/pcd14.160372PubMedGoogle Scholar 13.Crystal
YO , Marghalani
AA , Ureles
SD ,
et al. Use of silver diamine fluoride for dental caries management in children and adolescents, including those with special health care needs.
Pediatr Dent. 2017;39(5):135-145.
PubMedGoogle Scholar 21.Moyer
VA ; US Preventive Services Task Force. Prevention of dental caries in children from birth through age 5 years: US Preventive Services Task Force recommendation statement.
Pediatrics. 2014;133(6):1102-1111. doi:
10.1542/peds.2014-0483PubMedGoogle ScholarCrossref 22.Chou
R , Pappas
M , Dana
T ,
et al. Screening and interventions to prevent dental caries in children younger than 5 years: updated evidence report and systematic review for the US Preventive Services Task Force.
JAMA. Published December 7, 2021. doi:
10.1001/jama.2021.15658Google Scholar 24.Centers for Disease Control and Prevention. Recommendations for using fluoride to prevent and control dental caries in the United States.
MMWR Recomm Rep. 2001;50(RR-14):1-42.
PubMedGoogle Scholar 25.Hale
KJ ; American Academy of Pediatrics Section on Pediatric Dentistry. Oral health risk assessment timing and establishment of the dental home.
Pediatrics. 2003;111(5, pt 1):1113-1116.
PubMedGoogle Scholar 29.American Academy of Pediatric Dentistry. Fluoride therapy. In: The Reference Manual of Pediatric Dentistry. American Academy of Pediatric Dentistry; 2020:288-291.